Immunomedics (NASDAQ: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the publication of a preclinical study that shows milatuzumab, the Company's proprietary humanized anti-CD74 antibody, effectively prevents the onset and manifestations of acute graft-versus-host disease (GVHD) in a humanized-mouse model.
Acute GVHD is a medical complication following bone marrow or stem cell transplant. It occurs when white blood cells transplanted from a donor start attacking the recipient's body after recognizing the recipient's body as foreign. According to published reports, the number of stem cell transplantations continues to increase, with more than 20,000 transplantations from donors performed annually worldwide. In 2006, the estimated number of stem cell transplantations reported in the U.S. to the Center for International Blood and Marrow Transplant Research was 6,100 (3,800 related donors and 2,300 unrelated donors).
The global incidence of acute GVHD ranges from 26% to 34% in recipients of full matched sibling donor grafts, to 42% to 52% in recipients of matched unrelated donor grafts, and is a major cause of non-relapse mortality, with >50% 2-year non-relapse mortality inFlickr user The Wandering Angel]
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.